Castration resistant prostate cancer (CRPC) remains androgen dependant despite castrate
levels of circulating testosterone following androgen deprivation therapy, the first line of …

Simple Summary Castration-resistant prostate cancer (CRPC) is an advanced form of
prostate cancer with a low survival rate, as the CRPC patients only survive for 9–13 months …

Androgens exert important effects both in androgen-responsive tissues and in the intestinal
tract. To determine the impact of the gut microbiota (GM) on intestinal androgen metabolism …

Lethal prostate cancer (PCa) is characterized by the presence of metastases and
development of resistance to therapies. Metastases form in a multi-step process enabled by …

A comprehensive atlas of sex steroid distribution in multiple tissues is currently lacking, and
how circulating and tissue sex steroid levels correlate remains unknown. Here, we adapted …

Solid tumors have complex biology and structure comprising cancer cells, stromal cells, and
the extracellular matrix. While most therapeutics target the cancer cells, recent data suggest …

Castration resistance is in part attributable to aberrant activation of androgen receptor (AR)
signaling by the intracrine activation of androgen precursors derived from adrenal glands …

Dehydroepiandrosterone (DHEA), an adrenal androgen precursor, can be metabolized in
target tissues into active sex steroids. It has been proposed that DHEA supplementation …

Progesterone serum levels have been identified as a potential predictor for treatment effect
in men with advanced prostate cancer, which is an androgen-driven disease. Although …

Antiandrogen treatment resistance is a major clinical concern in castration-resistant prostate
cancer (CRPC) treatment. Using xenografts of VCaP cells we showed that growth of …